Monday, February 19, 2018 11:52:03 AM
I rarely have seen hype with Pluristem... maybe about 5 years ago when they announced their successes with what I think were 2 patients that had their symptoms resolved from anti cancer therapy and the price shot up to close to $5... I was there...
Without company disclosures being released...there will be little public awareness. The price will flounder where it is now.
But certainly, there is the danger of huge PUBLIC hype and then years of no deliveries. I believe this is the Celgene spinoff.
PSTI IS MILES AHEAD IN THE AREA OF APPROVALS. I mean we have late stage double blind placebo controls studies in huge markets. And let's not forget ARS.
My only concern with PSTI, is the secrecy in releasing data. As I mentioned earlier, my only disappointment is their inability to meet most of their deadlines and not disclosing information in a timely matter....
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM